Oncolytic virus therapy is amongst the most promising cancer treatments under development today. These innovative therapies use live, genetically modified viruses to target cancer cells and activate the body’s own immune defenses against the cancer. Oncolytic virus therapy may be able to deliver more targeted treatments for specific types of cancer with fewer negative side effects than traditional chemotherapies. To accelerate time to market and move promising oncolytic viral therapies through the pipeline, researchers and drug developers need the right nonclinical partner to gather the toxicology and other data they need to prepare for clinical trials.
AmplifyBio’s staff has been working with oncolytic viral therapies since 2013, and have established multiple custom rat and mouse tumor models for sponsors. AmplifyBio’s oncolytic virus therapy studies undergoes rigorous safety testing to provide insights on viability. This testing involves assessing the potential adverse effects on healthy cells and tissues, as well as monitoring for any unintended viral replication or systemic toxicity.
Through our internal efforts and through a longstanding partnership with Battelle, Amplifybio has curated a number of thought leadership resources for oncolytic virotherapy and many other globally utilized services. Oncolytic virotherapy is a promising approach in cancer treatment and by harnessing the tumor-killing potential of viruses, oncolytic virotherapy offers a novel and targeted strategy for combating various types of cancers.
Preclinical CRO services play a crucial role in drug development by conducting studies and experiments on potential therapeutics before they advance to clinical trials. AmplifyBio offers a wide-range of preclinical CRO services including:
As an expert contract research organization (CRO), AmplifyBio leverages decades of experience to create modern commercial drug development solutions. From CRO and preclinical CRO needs to cell and gene therapy and advanced therapy testing, our accredited team designs innovative paths to produce globally recognized studies, services, and more.